Breast Cancer Clinical Trial
Official title:
UK Trial Of Hormone Replacement Therapy (HRT) In Women With A History Of Early Stage Breast Cancer
Verified date | June 2005 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
RATIONALE: Hormone replacement therapy may be effective in relieving symptoms of menopause,
such as hot flashes, night sweats, and vaginal dryness, without causing a recurrence of
breast cancer.
PURPOSE: This randomized clinical trial is studying hormone replacement therapy to see how
well it works in relieving symptoms of menopause in postmenopausal women with previous stage
I or stage II breast cancer.
Status | Active, not recruiting |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility |
DISEASE CHARACTERISTICS: - Prior diagnosis of stage I or II breast cancer - No clinical evidence of recurrence - Meets criteria for 1 of the following: - Amenorrheic for at least the past 6 months - Radiotherapy- or chemically-induced ovarian suppression allowed - Prior surgical bilateral oophorectomy - Experiencing vasomotor symptoms (i.e., hot flashes or night sweats) with or without vaginal dryness - No undiagnosed postmenopausal bleeding - No ductal carcinoma in situ or lobular carcinoma in situ alone - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age - Postmenopausal Sex - Female Menopausal status - Postmenopausal Performance status - Not specified Life expectancy - Not specified Hematopoietic - Not specified Hepatic - No severe, active liver disease with abnormal liver function tests - No acute, intermittent porphyria - Fibrinolysis and coagulation normal Renal - Not specified Cardiovascular - No prior deep vein thrombosis - Thrombophlebitis or superficial phlebitis alone allowed - No prior retinal vein thrombosis Pulmonary - No prior pulmonary embolism Other - Not pregnant - No prior alcohol, drug, or chemical abuse - No other prior or concurrent malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No concurrent chemotherapy Endocrine therapy - More than 3 months since prior oral or transdermal hormone replacement therapy (HRT) - More than 5 years since prior HRT implant - No other concurrent HRT - No concurrent gonadotropin-releasing hormone agonists (e.g., goserelin) if less than 2 years of planned treatment remains - No other concurrent low-dose progestins - No concurrent tibolone - No concurrent phytoestrogens (e.g., black cohosh, red clover, or soy) Radiotherapy - See Disease Characteristics Surgery - See Disease Characteristics Other - No concurrent Hypericum perforatum (St. John's wort) |
Allocation: Randomized, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
United Kingdom | Institute of Cancer Research - UK | Sutton | England |
Lead Sponsor | Collaborator |
---|---|
Institute of Cancer Research, United Kingdom |
United Kingdom,
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |